Biotech company OMass Therapeutics has taken a new 16,000 sq ft mixed-use site at ARC Oxford.
ARC has fully refurbished the lab space of the building to meet OMass’ scientific and technical requirements and the office space has also been designed to “better enable collaborative working both on-site and virtually”.
David Williams, director of leasing at ARC, said: “We’re delighted to be supporting OMass Therapeutics on its growth journey. It’s a leading UK biopharma company at the forefront of innovation in drug discovery. The new building keeps it at the heart of a vibrant ecosystem of innovative companies in Oxford and offers access to communal, social and co-working spaces and a curated programme of events for campus members.”
Dan Williams, director of asset management at ARC Oxford, added: “We’re delighted that our community of life science organisations is expanding at ARC Oxford. This is testament to Oxfordshire’s thriving science and tech ecosystem, and we’re pleased that our investment into the campus is creating state-of-the-art, fitted laboratory space that fosters innovation and allows our members to continue their growth journey in today’s global economy.”
